RA and comparator arms, respectively, 55.3% women, with a mean age of 57.0 ± 3.8 years), treatment with GLP-1 RA was not associated with a significant increase in the incidence of atrial fibrillation [Mantel-Haenszel OR (95% CI) 0.87 (0.71-1.05), p = 0.15]. Conclusions In conclusion, available data suggest that GLP-1 RA is not associated with atrial fibrillation, with the only possible exception of albiglutide. Newly onset atrial fibrillation deserves to be investigated as an event of special interest in future trials with GLP-1 RA.
Introduction
The overall cardiovascular safety of glucagon-like peptide 1 receptor agonists (GLP-1 RA) has been demonstrated by three cardiovascular outcome trials (CVOT) [1] [2] [3] and several pooled analyses of phase III trials [4] [5] [6] [7] . Currently available evidence suggests that GLP-1 RA, or at least some components of the class, could be associated with a reduction of cardiovascular morbidity [2, 3] . However, the pharmacological stimulation of GLP-1 receptors is associated with an increase in heart rate [8] , which could be determined by direct stimulation of the GLP-1 receptor on sino-atrial cells [9] .
Recently, a pooled analysis of patient-level data from phase III trials with albiglutide revealed a significant increase in the risk of atrial fibrillation [7] . In two of the available CVOT with GLP-1 RA [1, 3] the incidence of atrial fibrillation with the active drug (lixisenatide or semaglutide) was not significantly different from placebo. In the other CVOT, the effect of liraglutide was not reported in
Abstract
Background The pharmacological stimulation of GLP-1 receptors is associated with an increase in heart rate. A pooled analysis of patient-level data from phase III trials with albiglutide revealed a significant increase in the risk of atrial fibrillation. Aim of the present meta-analysis is to summarize all available evidence on the effects of individual GLP-1 receptor agonists (RA), and of the whole class, on the incidence of atrial fibrillation. Methods A Medline search for GLP-1 RA (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥12 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 RA with placebo or any other non-GLP-1 RA drug. Results Of the 113 trials fulfilling the inclusion criteria, 19 did not report information on atrial fibrillation, whereas 63 reported zero events in all treatment groups. In the remaining trials (enrolling 17,966 and 15,305 patients in GLP-1 the main publication [2] , but it was disclosed on a public register (http://www.clinicaltrials.gov), again showing no significant between-group difference [10] .
Aim of the present meta-analysis is to summarize all available evidence on the effects of individual GLP-1 RA, and of the whole class, on the incidence of atrial fibrillation in patients with diabetes, in comparison with placebo or other active treatments.
Materials and methods
This analysis was performed as a post hoc analysis on data collected for a different systematic review, the protocol of which (CRD42015020245) was published on the University of York (Centre for Reviews and Dissemination) website [11] .
Data sources and searches
All randomized clinical trials on GLP-1 RA (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) published in English up to November 15, 2016 were retrieved from Medline/Embase and from http://www. clinicaltrials.gov website. The search string was exenatide OR liraglutide OR lixisenatide OR albiglutide OR dulaglutide OR semaglutide with the following limits: randomized clinical trials, English, humans. In addition, for approved drugs, Medical Reviews were retrieved from the Food and Drug Administration (FDA) website [12] , and the summary of product characteristics from the European Medicines Agency (EMA) website [13] , for the identification of further unpublished and otherwise undisclosed trials. Study selection and data extraction were performed independently by two of the authors (B.N., M.M.), and conflicts resolved by the third investigator (E.M.).
Study selection
All randomized clinical trials on patients with type 2 diabetes with a duration of treatment ≥12 weeks, comparing a GLP-1 RA with placebo or any other non-GLP-1 RA drug, provided that concurrent treatment was the same for all treatment arms, and that the doses of GLP-1 RA were among those approved by FDA and/or EMA.
Data extraction and quality assessment
Results of trials on atrial fibrillation were retrieved from the publications and, if unavailable, from FDA Medical Reviews, EMA Summaries of Product Characteristics, http://www.clinicaltrials.gov study results, and trial results on manufacturers' company websites. Cases of AF were identified as adjudicated cases, and, if unavailable, by cases reported as serious adverse events. Data retrieval was performed by two of the investigators (B.N. and A.S.), and conflicts resolved by a third investigator (E.M.). The quality of trials was assessed using the Cochrane Collaboration's Tool for Assessing Risk of Bias in randomized controlled trials; quality was not used as a criterion for the selection of trials, but only for descriptive purposes.
Data synthesis and analysis
The principal outcome of this analysis was the effect of GLP-1 RA, compared with placebo or other active drugs, on the incidence of atrial fibrillation. Heterogeneity was assessed using I 2 statistics, and publication/disclosure bias with funnel plots, the Begg adjusted rank correlation test [14, 15] , and Duval and Tweedie's trim and fill method. Considering the differences across trials in molecules, treatment schedules, inclusion criteria, and length of follow-up, a random-effects model was applied, calculating Mantel-Haenszel odds ratio with 95% confidence interval (MH-OR) for all atrial fibrillation, on an intention-to-treat basis, excluding trials with zero events. A sensitivity analysis was performed using Peto's method, and another one applying continuity correction, to consider also trials with zero events. A further sensitivity analysis was performed including only trials with cardiovascular events within their principal endpoints. Subgroup analyses were performed for different drugs of the class and different classes of comparators. All analyses were performed using Comprehensive Meta-analysis Version 2, Biostat. (Englewood, NJ, USA). The meta-analysis was reported following the PRISMA checklist [16] .
Results
Out of 1147 and 532 items identified through Medline/ Embase, http://www.clinicaltrials.gov and FDA/EMA websites, respectively, 113 trials were selected, as summarised in Figure 1 of Supplementary materials. The quality of trials (all with intention-to-treat analysis) was generally good (Table 1 of Supplementary materials). The trials fulfilling the inclusion criteria enrolled 33,167 and 26,683 patients in GLP-1 RA and comparator arms, respectively, with a weighed mean duration of treatment of 80.6 weeks. The main characteristics of the selected trials are reported in Table 1 and Table 1 of Supplementary materials. The search of http://www.clinicaltrials.gov website allowed the identification of 26 unpublished and undisclosed, although completed, trials (Table 2 of Supplementary materials). AF is not usually mentioned as exclusion criteria in trials with GLP-1 RA. Of the 113 trials fulfilling the inclusion criteria, 19 did not report information on atrial fibrillation whereas 63 reported zero events in all treatment groups. The principal analysis was, therefore, performed on 31 trials, with a At the sensitivity analysis with continuity correction, MH-OR was 0.84 (0.70-1.00), p = 0.045. When trials with different molecules were analysed separately, a trend toward an increase in the incidence of atrial fibrillation was observed with albiglutide, but between-group differences did not reach statistical significance (Fig. 2a) . No significant between-group differences were observed in subgroup analyses with different comparators (Fig. 2b) .
Discussion
It is well known that treatment with GLP-1 RA is associated with an increase in heart rate [8] . This phenomenon has been observed with different molecules of the class, including both short-and long-acting agents, and molecules with different degrees of homology to human GLP-1 [17] , suggesting a class effect. In fact, a direct action of GLP-1 and of its RA on sino-atrial cells has been hypothesized [9] , although the reduction of blood pressure [17] could also contribute to the increase in heart rate.
Tachycardia is associated with increased myocardial oxygen consumption and decreased coronary blood flow, thus augmenting the risk for myocardial ischemia [18] . Treatment with GLP-1 RA, despite the increase in heart rate [1] [2] [3] 19] , is not associated with increased risk for myocardial infarction or other coronary events [1] [2] [3] ; on the contrary, a trend toward a reduction of myocardial infarction has been observed in one cardiovascular outcome trial [2] . On the other hand, a positive chronotropic effect could increase the risk of tachyarrhythmia. A recent pooled analysis of patient-level data from phase 2-3 trials with albiglutide revealed an increased risk of atrial fibrillation with respect to comparators [20] .
The present meta-analysis appears to exclude any major effect of GLP-1 RA, as a class, on the risk of atrial fibrillation. In a sensitivity analysis with continuity correction, GLP-1 RA was associated with a small, albeit marginally significant, reduction in the incidence of AF. A trend toward an increased risk was observed only with albiglutide, but not with other molecules of the class. The fact that the difference between albiglutide and comparators did not reach statistical significance, unlike what reported in the previously cited analysis [20] is not surprising. In fact, meta-analyses of trial-level data, such as this one, are less sensitive than analyses of patient-level data.
Considering the small number of reported events, it is possible that the result with albiglutide is determined by the play of chance. In addition, it should be noted that patients enrolled in trials with different molecules have different characteristics, preventing reliable comparisons within the class: in fact, trials with lixisenatide, liraglutide, and semaglutide include cardiovascular outcome trials and, therefore, a majority of patients with prior cardiovascular events, many of whom treated with betablockers. Another issue is related to diagnostic accuracy: it is conceivable that cases of AF had a greater chance of being correctly identified in cardiovascular outcome trials, even when they were not part of the principal endpoints; on the other hand, in trials designed for metabolic endpoints, cases of AF are detected only when they are reported as serious adverse events. It is possible that some events of atrial fibrillation with other molecules were not reported as serious adverse events, and were, therefore, missed in the present analysis. However, we cannot exclude a different effect of individual GLP-1 RA on the risk of atrial fibrillation. In fact, although an increase of heart rate has been detected with the majority of GLP-1 RA, it is possible that this effect varies across molecules. It has been suggested that long-acting GLP-1 RA have a greater impact on heart rate than shorter acting agents, and that, among long-acting molecules, liraglutide and albiglutide increase heart rate to a greater extent than dulaglutide and exenatide LAR [17] . However, no relevant effect of liraglutide on the risk of atrial fibrillation was detectable.
Some limitations of the present meta-analysis should be clearly recognized. The apparent heterogeneity across trials with respect to AF suggests that the effects of GLP-1 RA could vary on the basis of treatment schedules and/or characteristics of patients. The relatively small number of trials with events for each molecule prevents a reliable meta-regression analysis on this issue. In addition, atrial fibrillation is not considered as a primary endpoint in available trials, and in most instances it is not even listed among events of special interest. As a consequence, reported cases of AF are, usually, those identified by the investigators as serious adverse events.
This analysis was targeted at a very specific issue, i.e., the effect of GLP-1 RA on atrial fibrillation. Further information on adverse events associated with these drugs, in the same data set, were reported in other publications [21, 22] .
In conclusion, available data suggest that albiglutide could be associated with an increase in the risk of atrial fibrillation, which is not observed with other GLP-1 RA. Newly onset atrial fibrillation deserves to be investigated as an event of special interest in future trials with GLP-1 RA.
